Drug Profile


Alternative Names: ZYAN-1; ZYAN1-1001

Latest Information Update: 09 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cadila Healthcare
  • Class Antianaemics
  • Mechanism of Action EGLN1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Anaemia

Most Recent Events

  • 09 Oct 2017 Cadila completes a phase I trial for Anaemia (In volunteers) in Australia and India (PO), before October 2017 (CTRI2016-02-006665) (ACTRN12614001240639)
  • 23 Jun 2017 Phase-II clinical trials in Anaemia in India (PO) before June 2017 (CTRI2017-05-008534) (Zydus Cadila pipeline, June 2017)
  • 31 May 2017 Cadila Healthcare plans a phase I trial for Anaemia in India (CTRI2017-05-008534)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top